Sep 29, 2026

Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics:

• Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00)
• Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09)
• Key findings from the Phase III ROSELLA study (7:06)
• Case: A woman in her early 50s with FIGO Stage IVB platinum-ineligible high-grade serous carcinoma of the fallopian tube enrolls in the Phase III ROSELLA study (15:02)
• Case: A woman in her late 40s with FIGO Stage IIIB platinum-ineligible high-grade serous ovarian carcinoma enrolls in the Phase II BELLA trial (23:42)

CME information and select publications